Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Immunotherapy: bewitched, bothered, and bewildered no more.

Steinman RM, Mellman I.

Science. 2004 Jul 9;305(5681):197-200.

PMID:
15247468
2.

Immune based therapies in cancer.

Kr├╝ger C, Greten TF, Korangy F.

Histol Histopathol. 2007 Jun;22(6):687-96. Review.

PMID:
17357098
3.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
4.

Dendritic cell immunotherapy: mapping the way.

Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ.

Nat Med. 2004 May;10(5):475-80. Review.

PMID:
15122249
5.

DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.

Schultze JL, Grabbe S, von Bergwelt-Baildon MS.

Trends Immunol. 2004 Dec;25(12):659-64. Review.

PMID:
15530836
6.

Immunotherapy with dendritic cells for cancer.

Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A.

Adv Drug Deliv Rev. 2008 Jan 14;60(2):173-83. Epub 2007 Oct 5. Review.

PMID:
17977615
7.

Dendritic cells in cancer immunotherapy.

Vulink A, Radford KJ, Melief C, Hart DN.

Adv Cancer Res. 2008;99:363-407. Review.

PMID:
18037410
8.

Challenges and prospects of immunotherapy as cancer treatment.

Rescigno M, Avogadri F, Curigliano G.

Biochim Biophys Acta. 2007 Sep;1776(1):108-23. Epub 2007 Jul 17. Review.

PMID:
17720322
9.

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. Epub 2007 May 15. Review.

PMID:
17503040
10.

Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.

Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT.

Cancer Metastasis Rev. 2006 Jun;25(2):233-42. Review.

PMID:
16770535
11.

Regulatory dendritic cells: new targets for cancer immunotherapy.

Shurin MR, Naiditch H, Zhong H, Shurin GV.

Cancer Biol Ther. 2011 Jun 1;11(11):988-92. Epub 2011 Jun 1. No abstract available.

PMID:
21474998
12.

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.

Lynch DH.

Immunol Rev. 2008 Apr;222:277-86. doi: 10.1111/j.1600-065X.2008.00621.x. Review.

PMID:
18364008
13.

Priming anticancer active specific immunotherapy with dendritic cells.

Mocellin S.

Curr Opin Investig Drugs. 2005 Jun;6(6):576-81. Review.

PMID:
15988908
14.

Modulation of antitumor responses by dendritic cells.

Vieweg J, Jackson A.

Springer Semin Immunopathol. 2005 Jan;26(3):329-41. Review.

PMID:
15609005
15.

Dendritic cell vaccines in melanoma: from promise to proof?

Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ.

Crit Rev Oncol Hematol. 2008 May;66(2):118-34. doi: 10.1016/j.critrevonc.2007.12.007. Epub 2008 Feb 8. Review.

PMID:
18262431
16.

Optimizing dendritic cell-based immunotherapy for cancer.

Zhong H, Shurin MR, Han B.

Expert Rev Vaccines. 2007 Jun;6(3):333-45.

PMID:
17542749
17.

Dendritic cells as therapeutic vaccines against cancer.

Banchereau J, Palucka AK.

Nat Rev Immunol. 2005 Apr;5(4):296-306. Review.

PMID:
15803149
18.

Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.

Breckpot K, Heirman C, Neyns B, Thielemans K.

J Gene Med. 2004 Nov;6(11):1175-88. Review.

PMID:
15468193
19.

Dendritic cell therapy of high-grade gliomas.

Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S.

Brain Pathol. 2009 Oct;19(4):694-712. doi: 10.1111/j.1750-3639.2009.00316.x. Review.

PMID:
19744041
20.

Cancer vaccines.

Chekhun VF.

Exp Oncol. 2008 Jun;30(2):90. No abstract available.

PMID:
18680872
Items per page

Supplemental Content

Write to the Help Desk